Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | GALR3 | O60755 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4032249 | 0.85 | TSHR (0.46) | TSHRALDH1A1CHRM2CHRM4CHRM1 | |
| SCHEMBL16627950 | 0.83 | TSHR (0.43) | TSHRALDH1A1CHRM2CHRM4CHRM1 | |
| SCHEMBL11599544 | 0.81 | TSHR (0.42) | TSHRALDH1A1CHRM2CHRM4CHRM1 | |
| SCHEMBL10368539 | 0.81 | TSHR (0.48) | TSHRALDH1A1CHRM2CHRM4CHRM1 | |
| SCHEMBL15965804 | 0.79 | TSHR (0.40) | TSHRALDH1A1CHRM2CHRM4CHRM1 | |
| SCHEMBL27427018 | 0.78 | TSHR (0.50) | TSHRALDH1A1CHRM2CHRM4CHRM1 | |
| SCHEMBL7170522 | 0.77 | ALDH1A1 (0.50) | TSHRALDH1A1CHRM2CHRM4CHRM1 | |
| SCHEMBL11857176 | 0.77 | TSHR (0.39) | TSHRALDH1A1CHRM2CHRM4CHRM1 | |
| SCHEMBL13848597 | 0.75 | TSHR (0.37) | TSHRTDP1LMNAKMT2A | |
| SCHEMBL4827195 | 0.75 | TSHR (0.37) | TSHRTDP1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230065629-A1 | SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-03-02 | — | — | US | disclosed |
| US-11208400-B2 | Substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-12-28 | — | — | US | disclosed |
| US-11208400-B2 | Substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-12-28 | — | — | US | disclosed |
| EP-3526212-B1 | SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | BAYER AG (DE) | 2021-12-22 | — | — | EP | disclosed |
| EP-3526212-B1 | SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | BAYER AG (DE) | 2021-12-22 | — | — | EP | disclosed |
| US-20200055842-A1 | SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2020-02-20 | — | — | US | disclosed |
| US-20200055842-A1 | SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2020-02-20 | — | — | US | disclosed |
| EP-3526212-A1 | SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | Bayer Aktiengesellschaft (DE) | 2019-08-21 | — | — | EP | disclosed |
| WO-2018069222-A1 | SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2018-04-19 | — | — | WO | disclosed |
| WO-2018069222-A1 | SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2018-04-19 | — | — | WO | disclosed |
| US-20100099672-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100099672-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100099672-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-7645881-B2 | Such as tert-Butyl 3-amino-5-ethyl-4,6-dimethylthieno[2,3-B]pyridine-2-carboxylate which inhibits replication | PTC THERAPEUTICS, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20060019976-A1 | Such as tert-Butyl 3-amino-5-ethyl-4,6-dimethylthieno[2,3-B]pyridine-2-carboxylate which inhibits replication | PTC THERAPEUTICS, INC. | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099672-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | TSHR 4336/4885ALDH1A1 539/4885CHRM2 3991/4885 |
| US-11208400-B2 | Substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof | REN, ATP6V1B1, GLS | TSHR 4285/4885ALDH1A1 211/4885CHRM2 3902/4885 |
| US-20060019976-A1 | Such as tert-Butyl 3-amino-5-ethyl-4,6-dimethylthieno[2,3-B]pyridine-2-carboxylate which inhibits replication | DIMT1, EIF2AK2, ELL | TSHR 4298/4885ALDH1A1 830/4885CHRM2 4774/4885 |
| US-20200055842-A1 | SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | REN, ATP6V1B1, GLS | TSHR 4285/4885ALDH1A1 211/4885CHRM2 3902/4885 |
| US-20230065629-A1 | SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | REN, ATP6V1B1, GLS | TSHR 4285/4885ALDH1A1 211/4885CHRM2 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.